Additionally, the ac4C score, a marker derivative of NAT10, shows promise as a robust prognostic indicator for immunotherapy responsiveness in PCa, providing a potentially more precise assessment of patient outcomes. The gene discussed is NAT10; the disease is posterior cortical atrophy.